Minerva Neurosciences, Inc.
NERV
$4.58
$0.6616.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 36.77% | -8.76% | |||
| Gross Profit | -36.77% | 8.76% | |||
| SG&A Expenses | -69.74% | 306.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.17% | 234.66% | |||
| Operating Income | 36.17% | -234.66% | |||
| Income Before Tax | 113.93% | 55.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 113.93% | 55.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 113.93% | 55.79% | |||
| EBIT | 36.17% | -234.66% | |||
| EBITDA | 36.17% | -234.73% | |||
| EPS Basic | 112.50% | 88.80% | |||
| Normalized Basic EPS | 113.12% | 88.80% | |||
| EPS Diluted | 95.17% | 88.80% | |||
| Normalized Diluted EPS | 107.73% | 88.80% | |||
| Average Basic Shares Outstanding | 6.15% | 294.86% | |||
| Average Diluted Shares Outstanding | 80.19% | 294.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||